NCT03894748View on ClinicalTrials.gov

Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2012

Conditions
Glabella Line Severity
Interventions
DRUG

Botulinum Toxin Type A

20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

Trial Locations (3)

Unknown

The Catholic University of Korea, St. Paul's Hospital, Seoul

Inha University Hospital, Incheon

Kyung Hee University Hospital at Gangdong, Seoul

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03894748 - Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L) | Biotech Hunter | Biotech Hunter